List of Excipients in Branded Drug CICLOPIROX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E Fougera & Co a division of Fougera Pharmaceuticals Inc	CICLOPIROX	ciclopirox	0168-0522	DISODIUM LAURETH SULFOSUCCINATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	CICLOPIROX	ciclopirox	0168-0522	LAURETH-2
E Fougera & Co a division of Fougera Pharmaceuticals Inc	CICLOPIROX	ciclopirox	0168-0522	SODIUM CHLORIDE

Generic Drugs Containing CICLOPIROX

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	ciclopirox	0168-0314	BENZYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	ciclopirox	0168-0314	CETYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	ciclopirox	0168-0314	COCO DIETHANOLAMIDE

What are the Most Frequently-Used Excipients in CICLOPIROX?

# Of NDCs	Excipient
1	((2S,3S,5S)-2-(2-(2,6-DIMETHYLPHENOXY)ACETAMIDO)-5-((S)-3-METHYL-2-(2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)BUTANAMIDO)-1,6-DIPHENYLHEXAN-3-YL) 3-METHYL-2-(2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)BUTANOATE
2	BENZYL ALCOHOL
1	BUTYL ESTER OF METHYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER

Ciclopirox Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Ciclopirox is an established topical antifungal with limited composition-of-matter protection and broad generic availability. The strongest commercial opportunities are formulation-led: improved nail penetration, shorter application cycles, better cosmetic performance, lower irritation, preservative-free delivery, and differentiated products for scalp, skin, vaginal, and pediatric use.

The most attractive development paths are optimized nail lacquers, water-based or low-solvent systems, ciclopirox olamine creams and foams, and prescription products supported by new clinical or pharmacokinetic data. Excipient selection will determine product performance because ciclopirox has low aqueous solubility, a strong tendency to partition into keratin, and formulation sensitivity around pH, solvent evaporation, film formation, and crystallization.

What dosage forms contain ciclopirox?

Ciclopirox is marketed in several topical dosage forms. Ciclopirox olamine is a salt form used in creams, lotions, gels, shampoos, and suspensions. Ciclopirox is used in the 8% nail lacquer product Penlac and generic equivalents.

Dosage form	Typical strength	Primary indication	Key formulation issue
Nail lacquer	8% ciclopirox	Mild to moderate onychomycosis	Nail penetration, durable film, removal burden
Cream	0.77% ciclopirox olamine	Dermatophyte and yeast skin infections	Skin tolerability, spreadability, preservative system
Lotion	0.77% ciclopirox olamine	Intertriginous and hairy skin areas	Low residue and uniform dosing
Gel	0.77% ciclopirox olamine	Seborrheic dermatitis and superficial fungal infections	Rheology, drying time, irritation
Shampoo	1% ciclopirox olamine	Seborrheic dermatitis	Foam, rinse performance, scalp deposition
Topical suspension	1% ciclopirox olamine	Scalp and skin conditions	Physical stability and redispersibility
Vaginal cream	Product-specific strength	Vulvovaginal fungal infection in certain markets	Mucosal tolerability and applicator compatibility

Commercial products vary by jurisdiction. U.S. FDA labeling confirms ciclopirox topical cream, gel, shampoo, suspension, and nail lacquer products, while approved indications and strengths depend on the specific application and product label (U.S. Food and Drug Administration [FDA], 2023a, 2023b).

What excipients are used in ciclopirox formulations?

Ciclopirox formulations commonly use solvents, surfactants, film-forming polymers, humectants, pH modifiers, preservatives, and viscosity agents. The excipient system should be designed around the target tissue rather than transferred between dosage forms.

Nail lacquer excipients

The original Penlac nail lacquer uses a volatile solvent and film-forming system that deposits ciclopirox on the nail plate. Generic products may use comparable or different excipient combinations, subject to regulatory requirements and product performance.

Important excipient classes include:

• Volatile solvents, such as ethyl acetate, isopropyl alcohol, and other alcohol or ester systems.
• Film-forming polymers, including cellulose derivatives and acrylic or methacrylate polymers.
• Plasticizers, which reduce brittleness and improve adhesion.
• Penetration enhancers, which may increase drug movement through the nail plate.
• Water or controlled water content, which affects drying, film morphology, and drug crystallization.
• Suspending or solubilizing agents, when the formulation is not a fully dissolved system.

The formulation must balance four competing properties: rapid drying, durable adhesion, sufficient drug release, and low cosmetic burden. A high-solvent product may dry quickly but cause brittleness or irritation. A stronger film can improve retention but increase removal difficulty and reduce patient adherence.

Cream, gel, and lotion excipients

Ciclopirox olamine creams and gels typically require:

• An oil phase or emollient system.
• Nonionic emulsifiers.
• Humectants such as propylene glycol or glycerol.
• Carbomer or cellulose-based rheology modifiers.
• Preservatives.
• pH adjusters.
• Skin-conditioning agents.

Propylene glycol can function as both a humectant and penetration enhancer, but its concentration must be controlled because it can cause irritation in sensitive skin. Alcohols may improve drying and antimicrobial preservation but can increase stinging on damaged skin.

A low-residue gel has commercial value for scalp and hairy areas. A cream with enhanced barrier support may be more attractive for intertriginous or eczematous skin. The two products should not share the same excipient profile solely to simplify manufacturing.

Shampoo and suspension excipients

Ciclopirox olamine shampoo requires a surfactant system that cleans the scalp without stripping the barrier or destabilizing the active ingredient. Relevant excipients include:

• Anionic, amphoteric, or nonionic surfactants.
• Foam stabilizers.
• Suspending agents.
• Chelating agents.
• Preservatives.
• pH buffers.
• Conditioning polymers.

Ciclopirox shampoo development can focus on improved wetting, reduced fragrance, low-irritation surfactants, and better scalp contact time. A transparent or pearlescent product may improve consumer acceptance, but appearance should not compromise dose uniformity or suspension stability.

How does ciclopirox solubility affect excipient selection?

Ciclopirox has limited water solubility, while ciclopirox olamine has different ionization and solubility behavior. The active ingredient can remain dissolved in a solvent-rich system or precipitate during manufacturing, storage, application, or solvent evaporation.

A formulation program should characterize:

1. Solubility across pH values.
2. Solubility in individual solvents and mixed-solvent systems.
3. Drug crystallization during drying.
4. Particle size if the product is a suspension.
5. Partitioning into nail keratin or skin.
6. Compatibility with polymers, preservatives, and packaging.
7. Viscosity and spreadability over the labeled shelf life.

The most important development risk is a formulation that passes initial assay testing but produces a different drug state after application. A lacquer may contain dissolved ciclopirox in the bottle but form crystals as solvent evaporates. Those crystals may reduce release and nail penetration.

Excipient screening should therefore include drying-film microscopy, differential scanning calorimetry, X-ray diffraction, Raman or infrared analysis, and in vitro release testing. Nail permeation studies should use human cadaver nail or validated keratin models rather than relying only on membrane diffusion.

What excipient strategies can improve ciclopirox nail delivery?

The nail is a difficult barrier because its dense keratin structure limits diffusion. Penetration improvement is the main formulation opportunity for ciclopirox.

Strategy 1: Optimize the volatile solvent system

A mixed solvent system can control:

• Solubility in the bottle.
• Drying rate.
• Film uniformity.
• Crystallization.
• Nail wetting.
• Patient-perceived odor.

Ethyl acetate and alcohol-based systems can provide rapid evaporation. Slower co-solvents may improve film formation but increase drying time. The commercial objective is a dry film that remains sufficiently hydrated or flexible to support drug diffusion.

Strategy 2: Use film-forming polymers with controlled permeability

Film-forming polymers should provide adhesion without creating an impermeable barrier. Candidate classes include:

• Cellulose derivatives.
• Polyvinyl polymers.
• Acrylic copolymers.
• Methacrylate copolymers.
• Biodegradable or water-dispersible film systems.

A polymer change can create a differentiated product if it produces measurable improvement in nail drug levels, retention, or removal frequency. The strongest claims would link polymer composition to a defined performance outcome, such as reduced application frequency or increased drug deposition in the nail plate.

Strategy 3: Add penetration enhancers

Potential penetration-enhancer classes include alcohols, glycols, fatty acids, esters, urea derivatives, and selected surfactants. The commercial risk is irritation, excessive nail dehydration, or poor film integrity.

A successful enhancer should increase drug delivery without materially increasing adverse events. The product should also preserve cosmetic acceptability, because nail lacquer users may discontinue treatment when the film becomes opaque, brittle, or difficult to remove.

Strategy 4: Develop water-based or low-VOC systems

A water-based ciclopirox lacquer could address odor, flammability, and environmental concerns associated with solvent-rich products. The technical barriers are substantial:

• Ciclopirox solubility.
• Drying speed.
• Preservation.
• Film formation.
• Nail adhesion.
• Microbial control.
• Stability after repeated package opening.

A water-dispersible polymer or polymeric nanoparticle system could create a differentiated product. Regulatory positioning would depend on whether the product is pharmaceutically equivalent to an existing generic or requires a new drug application, a 505(b)(2) application, or another jurisdiction-specific pathway.

What formulation patents could protect ciclopirox products?

Ciclopirox composition-of-matter protection is no longer the primary barrier. Formulation patents would need to protect a specific technical combination and provide a measurable benefit.

Potential claim categories include:

Patent category	Example claim focus	Commercial value
Nail lacquer composition	Ciclopirox, solvent ratio, polymer, enhancer	Protects generic differentiation
Low-solvent formulation	Reduced volatile organic compounds with defined drying profile	Supports environmental and tolerability positioning
Nail penetration	Excipient combination producing higher nail deposition	Supports efficacy claims
Removal technology	Water-removable or peelable film	Improves adherence
Long-acting product	Extended-release polymer matrix or depot film	Enables less frequent application
Foam or gel	Ciclopirox olamine with defined surfactant and rheology system	Differentiates scalp and skin products
Preservative-free system	Packaging and formulation combination	Supports sensitive-skin use
Manufacturing process	Mixing, dissolution, drying, or particle-control process	Protects scale-up know-how
Packaging	Brush, applicator, unit dose, or airless container	Protects delivery and stability

Patent strength depends on whether the claims require a narrow excipient ratio or cover a broad genus. A narrow claim may be easier to obtain but easier to design around. A broad claim requires strong support across multiple solvent, polymer, and drug-concentration combinations.

Method-of-use patents can supplement formulation claims. Examples include treating defined grades of onychomycosis, reducing application frequency, treating patients with diabetes, or using a product after mechanical debridement. Such claims require credible clinical evidence and may face narrower enforceability than composition claims.

What is the FDA and Orange Book status of ciclopirox?

U.S. ciclopirox products are prescription topical drugs. Penlac nail lacquer was approved by FDA for mild to moderate onychomycosis caused by susceptible organisms. FDA-approved generic versions of ciclopirox nail lacquer have entered the market, confirming that the product is subject to generic competition (FDA, 2023a).

The principal regulatory points are:

Issue	Assessment
FDA status	Approved topical antifungal products
Reference nail product	Penlac, ciclopirox 8% nail lacquer
Generic competition	Present
Composition-of-matter exclusivity	Expired
Primary remaining protection	Formulation, method of use, process, packaging, and trade secrets
Biosimilar risk	Not applicable; ciclopirox is a small-molecule drug
Paragraph IV risk	Relevant only where an active listed patent remains for the targeted reference product
505(b)(2) opportunity	Possible for materially different delivery systems or new clinical use

Orange Book patent exposure must be reviewed by product and edition because listings can change over time. An investor or licensee should verify the current FDA Orange Book entry, approved labeling, listed patents, exclusivity codes, and any approved generic applications before relying on a specific launch date (FDA, 2024).

When does ciclopirox lose exclusivity?

Ciclopirox lost practical market exclusivity years ago. The relevant commercial question is no longer the expiration of the original active-ingredient patent. It is whether a new formulation can obtain enforceable protection long enough to support development costs.

Generic entry risks are high for conventional ciclopirox creams, gels, shampoos, and nail lacquers. A new product requires a stronger commercial rationale if it uses the same active ingredient, strength, route, and indication as an established generic.

A differentiated product can create a new exclusivity window through:

• A new dosage form.
• A new strength.
• A new indication.
• A new delivery system.
• A clinically meaningful dosing reduction.
• A new patient population.
• A combination product.
• A new 505(b)(2) approval with associated regulatory exclusivity.

Five-year new chemical entity exclusivity is generally unavailable for a previously approved active ingredient. Three-year exclusivity may be possible for an application supported by new clinical investigations essential to approval. Orphan-drug exclusivity could apply only if the product qualifies for an orphan indication and meets the applicable statutory requirements.

Which companies are challenging ciclopirox products?

Generic competition comes from manufacturers of ciclopirox olamine creams, gels, shampoos, suspensions, and ciclopirox nail lacquer. The market is fragmented across branded dermatology companies, generic manufacturers, contract manufacturers, and regional distributors.

The competitive landscape includes:

• Generic manufacturers seeking ANDA approval for established dosage forms.
• Dermatology companies licensing improved topical delivery technologies.
• Specialty pharmaceutical companies pursuing 505(b)(2) products.
• Consumer-health companies evaluating OTC-adjacent antifungal positioning.
• Contract development and manufacturing organizations with ready-made lacquer, gel, or foam platforms.

Ciclopirox does not face biosimilar competition because it is a synthetic small molecule. The competitive threat is substitution by terbinafine, azoles, amorolfine in certain jurisdictions, efinaconazole, tavaborole, and newer topical or oral antifungal products.

How does ciclopirox compare with competing antifungals?

Product	Main opportunity	Main limitation
Ciclopirox 8% lacquer	Established nail product with formulation flexibility	Long treatment duration and application burden
Efinaconazole 10% solution	Convenient brush-on nail delivery and strong commercial positioning	Higher cost and patent history
Tavaborole 5% solution	Nail penetration and non-lacquer format	Cost and clinical positioning
Amorolfine lacquer	Less frequent application in some markets	Geographic availability varies
Oral terbinafine	Higher systemic efficacy for many nail infections	Drug interactions, monitoring, systemic exposure
Topical azoles	Broad skin and yeast indications	Variable nail penetration
Ciclopirox olamine cream	Familiar topical antifungal with broad dermatology use	Generic price competition

Ciclopirox’s commercial advantage is formulation latitude and a long safety history. Its weakness is the need to compete against lower-cost generics and newer nail products with easier application schedules.

What licensing deals and commercial partnerships are most attractive?

The most valuable licensing opportunities involve a formulation platform that can be reused across ciclopirox and other topical antifungals. A partner is more likely to pay for a platform with data showing improved nail delivery, reduced dosing frequency, or better tolerability than for a conventional ciclopirox generic.

Potential deal structures include:

• Regional licensing of a novel nail lacquer.
• Co-development of a 505(b)(2) product.
• Out-licensing of a preservative-free dermatology platform.
• Supply agreements for a proprietary polymer or enhancer.
• Brand licensing for a differentiated generic.
• Milestone-based deals tied to FDA acceptance, clinical proof of concept, and approval.
• Revenue-sharing arrangements with specialty dermatology companies.

The strongest diligence package would include comparative nail deposition data, stability data, human tolerability data, manufacturing scale-up results, and a claim chart against listed patents and published prior art.

What generic launch scenarios exist for ciclopirox?

Conventional generic substitution

This is the lowest-risk regulatory path but also the least attractive economically. Price erosion is likely when several ANDA products compete.

Premium generic nail lacquer

A manufacturer could use improved drying, reduced odor, lower removal burden, or a better applicator to support a branded-generic strategy. The product would still face rapid substitution unless the benefit is visible to prescribers and patients.

505(b)(2) long-acting nail product

A reduced-frequency product could support premium pricing and regulatory exclusivity. The development burden is higher because the sponsor must establish the relationship between formulation changes, exposure, and clinical outcomes.

New topical foam or spray

A ciclopirox olamine foam or spray could target hairy areas, seborrheic dermatitis, or patients who dislike creams. The principal value would come from convenience and patient adherence rather than new pharmacology.

Combination product

Combining ciclopirox with a keratolytic, anti-inflammatory, barrier-repair, or antiseptic agent could address mixed disease biology. Combination development increases clinical, compatibility, and regulatory complexity.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are moderate for creams and gels but higher for nail lacquers and advanced delivery systems. Critical process parameters include:

• Order of excipient addition.
• Temperature during dissolution.
• Water content.
• Polymer hydration.
• Mixing shear.
• Solvent evaporation.
• Particle-size control.
• Filling under controlled conditions.
• Brush or applicator consistency.
• Container-closure compatibility.

For solvent-rich lacquers, flammability controls and facility classification can increase capital costs. Packaging must limit evaporation and maintain dose delivery through the full use period. Brush geometry can affect applied volume, coverage, and nail penetration.

Trade-secret protection may be more valuable than patents for solvent ratios, mixing conditions, polymer hydration, and filling parameters. Patent protection is preferable where the formulation benefit can be demonstrated and the product is likely to attract generic substitution.

Key Takeaways

• Ciclopirox has little remaining value as an unprotected conventional generic but retains formulation-led commercial potential.
• The strongest opportunity is a nail product with improved penetration, faster drying, lower removal burden, or less frequent dosing.
• Excipient selection should control drug solubility, film formation, crystallization, nail wetting, and tolerability.
• Ciclopirox olamine creams, gels, shampoos, and foams offer lower technical risk but face intense generic competition.
• Ciclopirox is not exposed to biosimilar competition.
• Formulation patents, method-of-use patents, process claims, packaging claims, and trade secrets are the relevant protection tools.
• A 505(b)(2) strategy may support regulatory exclusivity where the new delivery system requires clinical evidence.
• Conventional products are vulnerable to generic price erosion, while differentiated products require clinical or performance data that justify premium pricing.

FAQs About Ciclopirox Excipient and Commercial Strategy

Can ciclopirox be formulated as a water-based nail lacquer?

Yes. A water-based system is technically possible but must address low drug solubility, drying time, film adhesion, preservation, and nail penetration. A polymer dispersion or controlled-release particulate system may be required.

Which excipients are most important for ciclopirox nail penetration?

Solvents, glycols, selected surfactants, fatty-acid derivatives, urea-related enhancers, and film-forming polymers are the main variables. The best system depends on the balance between drug release, nail hydration, irritation, and film integrity.

Is ciclopirox a good candidate for an OTC product?

The active ingredient has established topical use, but an OTC switch would require FDA review of the indication, labeling, safety, consumer-use profile, and applicable monograph or nonmonograph pathway. A prescription-to-OTC strategy would require more than simply changing excipients.

Can a new ciclopirox formulation receive three-year FDA exclusivity?

Potentially, if the application relies on new clinical investigations essential to approval and otherwise satisfies the statutory requirements. A routine generic formulation change without essential new clinical data would not normally support three-year exclusivity.

What is the best commercial indication for a new ciclopirox product?

Onychomycosis offers the largest formulation differentiation opportunity because nail delivery and treatment adherence remain difficult. Seborrheic dermatitis and superficial skin infections offer lower development risk but face more direct generic competition.

References

1. U.S. Food and Drug Administration. (2023a). Penlac ciclopirox 8% nail lacquer prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023b). Ciclopirox olamine topical products prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Gupta, A. K., Stec, N., Summerbell, R. C., Shear, N. H., Piguet, V., Tosti, A., & Piraccini, B. M. (2019). Onychomycosis: A review. Journal of the American Academy of Dermatology, 80(4), 1012-1021.

5. Baran, R., Hay, R. J., Haneke, E., Tosti, A., & Bonafé, J. L. (1999). Onychomycosis: The current approach to diagnosis and therapy. Taylor & Francis.

6. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.